A Patient's Guide to Understanding Clinical Trial Data

Clinical trial data is the foundation of evidence-based cancer treatment - and increasingly, patients want to understand what the numbers actually mean. This guide explains the key concepts behind how trials are designed and how their results should be interpreted.

Trial phases

Clinical trials progress through phases that serve different purposes. Phase 1 trials establish safety - testing a new drug in small numbers of patients to find an appropriate dose and identify serious adverse effects. Phase 2 trials assess preliminary efficacy - is there a signal that the drug is working? Phase 3 trials are the large, randomised studies that establish whether a drug is better than the current standard of care. These are the trials that form the basis of regulatory approval. Long-term follow-up studies extend the observation period to capture data on durability and late effects.

Key endpoints explained

Clinical trials measure outcomes using defined endpoints:

• Overall survival (OS): How long patients live. The most important endpoint - it is hard to argue with. Median OS is the point at which 50% of patients in a group are still alive.
• Progression-free survival (PFS): How long patients live without their disease worsening. A useful measure but not a direct substitute for overall survival - a treatment can improve PFS without necessarily improving OS.
• Objective response rate (ORR): The proportion of patients whose tumour shrinks by a defined amount (complete or partial response). A high ORR is encouraging but does not tell you how long the response lasts.
• Duration of response (DoR): How long a response lasts in patients who achieve one. An important companion to ORR.

Median versus individual outcomes

Median values describe the midpoint of a distribution - half of patients do better, half do worse. A median OS of 14 months does not mean every patient lives 14 months: some live much shorter and some much longer. For immunotherapy, where a subset of patients achieve very durable responses, median figures can underrepresent the potential benefit for the best-responding patients.

What trial data means for you personally

Trial populations are defined groups with specific eligibility criteria. Whether you are similar to the patients in a trial affects how applicable its results are to you. The same absolute result - a 30% response rate, for example - means very different things for a patient with high PD-L1 expression treated in the first line versus a heavily pre-treated patient with low PD-L1. Interpreting what the evidence means for your specific situation requires a qualified oncologist who knows your clinical details.